PARIS, Oct. 30 — Treatment with axitinib resulted in at least a partial response in nearly half of patients with cytokine-refractory metastatic kidney cancer, investigators in a multinational trial have found. Action Points
Explain to interested patients that a drug that blocks a tumor’s ability to form blood vessels has shown promise for treating advanced kidney cancer.
Note that the drug is the third of its type to demonstrate activity in kidney cancer.
Note also that this particular drug is not yet available, although two others like it are available.